ERS Genomics published a new drug-design framework that learns directly from every compound synthesised in the lab, including failures and candidates rejected on developability grounds.
Public source
Publisher name
Public post
A new drug-design framework learns directly from every compound synthesised in the lab, including failures and candidates rejected on developability grounds. RCDO feeds…
Company
ERS Genomics
The global CRISPR/Cas9 licensing leader
- Industry
- Biotechnology Research
- Location
- San Francisco, US
- Company size
- 11–50 employees
About ERS Genomics
ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development. To learn more about acquiring your license, contact us today.
See moreLatest activity
Latest activity from ERS Genomics
4 signals
Research & Knowledge
ERS Genomics CEO John E. Milad explores how the shift from bespoke experimentation towards engineering discipline is changing the next phase of synthetic biology in the latest Monthly Cut.
Research & Knowledge
ERS Genomics CEO John E. Milad explores how CRISPR has become part of the core toolkit of synthetic biology and industrial bioproduction in The Monthly Cut
Research & Knowledge
ERS Genomics published an article exploring challenges in synthetic biology and biomanufacturing in The Monthly Cut, The SynBio Scale-Up
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
RoukenBio
RoukenBio published a study in Nature Biotechnology by M Frank Erasmus et al. regarding artificial intelligence in silico affinity maturation and developable designs.
Research & Knowledge
Terns Pharmaceuticals
Terns Pharmaceuticals published a recent paper showing that Reinforcement Learning with Metacognitive Feedback (RLMF) improves an AI's ability to signal uncertainty by up to 63% compared to standard methods.
Research & Knowledge
Ardigen
Ardigen published research from the University of Bonn and collaborating German institutes using RFdiffusion, ProteinMPNN, and structure-prediction models to design thousands of compact protein minibinders against cancer-associated surface targets including PD-L1, CD276, and VTCN1.
Research & Knowledge
Insilico Medicine
Insilico Medicine was featured in a Forbes/BernardMarr.com article by Bernard Marr exploring how the company is moving past early AI proofs-of-concept to build a repeatable, scalable engine for biopharma innovation.
Research & Knowledge
Deep Origin